PL3464276T3 - Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu - Google Patents
Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamiduInfo
- Publication number
- PL3464276T3 PL3464276T3 PL17724052T PL17724052T PL3464276T3 PL 3464276 T3 PL3464276 T3 PL 3464276T3 PL 17724052 T PL17724052 T PL 17724052T PL 17724052 T PL17724052 T PL 17724052T PL 3464276 T3 PL3464276 T3 PL 3464276T3
- Authority
- PL
- Poland
- Prior art keywords
- indazol
- ylamino
- tetrahydropyran
- piperazin
- benzamide
- Prior art date
Links
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340797P | 2016-05-24 | 2016-05-24 | |
| PCT/EP2017/061919 WO2017202674A1 (en) | 2016-05-24 | 2017-05-18 | New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| EP17724052.0A EP3464276B1 (en) | 2016-05-24 | 2017-05-18 | New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydropyran-4-ylamino)-benzamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3464276T3 true PL3464276T3 (pl) | 2022-04-04 |
Family
ID=58709993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17724052T PL3464276T3 (pl) | 2016-05-24 | 2017-05-18 | Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10738037B2 (enExample) |
| EP (2) | EP3464276B1 (enExample) |
| JP (2) | JP7094228B2 (enExample) |
| KR (1) | KR102441736B1 (enExample) |
| CN (1) | CN109153669B (enExample) |
| AU (1) | AU2017271458B2 (enExample) |
| CA (1) | CA3024208C (enExample) |
| ES (1) | ES2899953T3 (enExample) |
| IL (1) | IL263004B (enExample) |
| MX (1) | MX379558B (enExample) |
| PL (1) | PL3464276T3 (enExample) |
| WO (1) | WO2017202674A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109153669B (zh) * | 2016-05-24 | 2021-12-24 | 内尔维阿诺医学科学有限公司 | 苯甲酰胺类化合物的新晶型 |
| WO2021018928A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | New pharmaceutical formulation |
| WO2021084260A1 (en) * | 2019-11-01 | 2021-05-06 | Johnson Matthey Public Limited Company | Crystalline entrectinib anhydrate and monohydrate forms; crystalline entrectinib thf, nitromethane, isopropyl acetate and methanol solvate forms; processes for preparing a crystalline entrectinib anhydrate form |
| CN113024521B (zh) * | 2019-12-09 | 2023-01-17 | 武汉九州钰民医药科技有限公司 | 一种制备恩曲替尼的方法 |
| CN111171009B (zh) * | 2020-01-10 | 2022-07-12 | 安礼特（上海）医药科技有限公司 | 恩曲替尼晶型及其制备方法 |
| CN113354626B (zh) * | 2020-03-04 | 2025-06-03 | 罗欣药业(上海)有限公司 | 恩曲替尼的晶型及其制备方法 |
| CN113801062B (zh) * | 2020-06-15 | 2023-05-26 | 沈阳药科大学 | 3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法 |
| CN112336723B (zh) * | 2020-12-11 | 2023-09-26 | 江南大学 | 制备用于降低trpv4与nox2耦联度的药物的方法 |
| CN116669735A (zh) | 2021-02-03 | 2023-08-29 | 齐鲁制药有限公司 | 恩曲替尼晶型及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG183049A1 (en) * | 2007-07-20 | 2012-08-30 | Nerviano Medical Sciences Srl | Substituted indazole derivatives active as kinase inhibitors |
| PL3290414T3 (pl) * | 2012-05-23 | 2020-01-31 | Nerviano Medical Sciences S.R.L. | Sposób otrzymywania n-[5-(3,5-difluorobenzylo)-1h-indazol-3-ilo]-4-(4-metylopiperazyn-1-ylo)-2-(tetrahydropiran-4-yloamino)benzamidu |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| CN109153669B (zh) | 2016-05-24 | 2021-12-24 | 内尔维阿诺医学科学有限公司 | 苯甲酰胺类化合物的新晶型 |
-
2017
- 2017-05-18 CN CN201780031576.6A patent/CN109153669B/zh active Active
- 2017-05-18 AU AU2017271458A patent/AU2017271458B2/en active Active
- 2017-05-18 EP EP17724052.0A patent/EP3464276B1/en active Active
- 2017-05-18 US US16/301,826 patent/US10738037B2/en active Active
- 2017-05-18 ES ES17724052T patent/ES2899953T3/es active Active
- 2017-05-18 MX MX2018014298A patent/MX379558B/es unknown
- 2017-05-18 JP JP2018561474A patent/JP7094228B2/ja active Active
- 2017-05-18 WO PCT/EP2017/061919 patent/WO2017202674A1/en not_active Ceased
- 2017-05-18 EP EP21188238.6A patent/EP3967689A1/en not_active Withdrawn
- 2017-05-18 CA CA3024208A patent/CA3024208C/en active Active
- 2017-05-18 KR KR1020187037182A patent/KR102441736B1/ko active Active
- 2017-05-18 PL PL17724052T patent/PL3464276T3/pl unknown
-
2018
- 2018-11-14 IL IL263004A patent/IL263004B/en unknown
-
2020
- 2020-06-26 US US16/912,965 patent/US11091469B2/en active Active
- 2020-11-06 JP JP2020185594A patent/JP7154271B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3024208C (en) | 2022-07-26 |
| KR102441736B1 (ko) | 2022-09-13 |
| HK1259405A1 (zh) | 2019-11-29 |
| IL263004A (en) | 2018-12-31 |
| CN109153669B (zh) | 2021-12-24 |
| MX2018014298A (es) | 2019-03-14 |
| US20200325122A1 (en) | 2020-10-15 |
| JP2021042213A (ja) | 2021-03-18 |
| WO2017202674A1 (en) | 2017-11-30 |
| KR20190005236A (ko) | 2019-01-15 |
| US20190169173A1 (en) | 2019-06-06 |
| CN109153669A (zh) | 2019-01-04 |
| US10738037B2 (en) | 2020-08-11 |
| EP3464276B1 (en) | 2021-09-01 |
| MX379558B (es) | 2025-03-11 |
| ES2899953T3 (es) | 2022-03-15 |
| AU2017271458B2 (en) | 2020-11-26 |
| EP3967689A1 (en) | 2022-03-16 |
| EP3464276A1 (en) | 2019-04-10 |
| IL263004B (en) | 2022-04-01 |
| AU2017271458A1 (en) | 2019-01-17 |
| JP2019516749A (ja) | 2019-06-20 |
| BR112018073951A2 (pt) | 2019-02-26 |
| JP7154271B2 (ja) | 2022-10-17 |
| JP7094228B2 (ja) | 2022-07-01 |
| US11091469B2 (en) | 2021-08-17 |
| CA3024208A1 (en) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3464276T3 (pl) | Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu | |
| IL260297A (en) | Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide | |
| IL266214B (en) | 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors | |
| IL273786A (en) | New sulfonamide carboxamide compounds | |
| IL272555A (en) | New sulfonamide carboxamide compounds | |
| IL272550A (en) | New sulfonamide carboxamide compounds | |
| IL271716A (en) | New sulfonamide carboxamide compounds | |
| IL274488A (en) | Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| ZA201605424B (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use | |
| IL252368B (en) | 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it | |
| SI2981520T1 (sl) | Novi proces za sintezo 1-(2-((2,4-dimetilfenil)tio)fenil)piperazina | |
| MX2021015102A (es) | Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r). | |
| DK2987791T3 (da) | 3-(4-(Benzyloxy)phenyl)hex-4-insyre-derivat, egnet til forebyggelse og behandling af metaboliske sygdomme | |
| IL252900B (en) | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
| UY37517A (es) | Métodos de síntesis de compuestos tiazoles sustituidos | |
| PL3207928T3 (pl) | Preparat złożony, zawierający nową pochodną kwasu 3-(4-(benzyloksy)fenylo)heks-4-ynowego oraz inny składnik czynny, przeznaczony do zapobiegania lub leczenia chorób metabolicznych | |
| HUE063043T2 (hu) | Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására | |
| DK3395342T3 (da) | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf | |
| MA50972A (fr) | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide | |
| ZA202003028B (en) | Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative | |
| EP3475299A4 (en) | CONNECTIONS FOR TREATING METABOLISM DISORDERS | |
| EP3302466A4 (en) | 3-(phenyl)-n-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of cftr protein mediated diseases | |
| IL250412B (en) | Process for the production of n-[4-(1-(cyclobutylpiperidine-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride | |
| HK40086116B (zh) | 用作dhodh抑制剂的2，4，5-三取代的1，2，4-三唑酮 | |
| PL3153022T3 (pl) | N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid |